Articles related to OVARIAN CANCER

The study followed nearly 143,000 women who underwent hysterectomy for a benign condition over a 20-year-period and compared outcomes between those who had bilateral salpingo-oophorectomy (BSO) and those who didn’t. Younger (under age 45) women who had BSO had a higher 10-year cumulative risk of hospitalization for CVD. Women aged 45 to 54 with BSO had a higher 10-year risk for developing cancer. Based on the findings, the authors suggest a cautious approach to ovarian removal in postmenopausal women and recommend preserving ovaries in premenopausal women without a high risk for ovarian cancer.

Researchers examined the OTC drug shopping patterns of 153 women before being diagnosed with ovarian cancer and compared them to the patterns seen in 120 women without ovarian cancer. Participants in the study also answered questions regarding the symptoms they had and the number of times they had seen their general practitioner in the year preceding a cancer referral or diagnosis. Eight months before diagnosis, there was a substantial difference in the OTC drug buying habits of women with and without ovarian cancer. Up to nine months prior to diagnosis, there was a rise in the purchasing of dyspepsia medications.

In this on-demand webinar, a trio of Roswell Park Comprehensive Cancer Center experts share their wisdom on ovarian, cervical, and endometrial cancers. Dr. Emese Zsiros, Chair of Gynecologic Oncology, hosts the event with presenters Drs. Karen McLean and Katherine LaVinge Mager, Associate Professor of Oncology and Assistant Professor of Oncology in the Department of Gynecologic Oncology, respectively.

This update is based on the results from the June 2022 ATHENA-MONO2 phase III multinational, double-blind, randomized controlled trial (RCT), which showed a significant improvement in progression-free survival (PFS) in patients with stage III-IV epithelial ovarian cancer (EOC) who are in complete or partial response to first-line platinum-based chemotherapy.

Until a tumor is determined to be TMB-high or MSI-H/MMRd, and thus qualifies for treatment with pembrolizumab or dostarlimab on the basis of cancer site-agnostic approval, there is no justification for the use of single-agent ICB in unselected populations with recurrent EOC. However, the clinical trials carried out up to this point show that ICB can induce long-lasting responses in a relatively small fraction of individuals. These discoveries offer opportunities and challenges to the medical and scientific communities, including the need to use novel technologies to locate predictive biomarkers and create immunotherapies that go beyond ICB to improve the effectiveness of these drugs.

A Q&A session with Thomas J. Herzog, MD, the Deputy Director at the University of Cincinnati Cancer Center in Ohio, who discusses the PARP inhibitors olaparib (Lynparza, AstraZeneca), niraparib (Zejula, GSK), and rucaparib (Rubraca, Clovis Oncology); the ATHENA-MONO, ENGOT-OV16/NOVA, SOLO2, and ARIEL3 clinical trials; and the implications of the “Dear Health Care Provider” letters that were issued earlier this year regarding PARP inhibitors.